Please provide your email address to receive an email when new articles are posted on . Mean attack rates fell by 71% for patients with poorly controlled disease. Angioedema Control Test Scores rose ...

Please provide your email address to receive an email when new articles are posted on . Patients fit into one of four groups based on monthly hereditary angioedema attacks before lanadelumab. Along ...

The FDA awards Fast Track designation to BW-20805 for hereditary angioedema, a therapy designed to reduce attacks through PKK suppression.

Rapid swelling from hereditary angioedema can result from a variety of triggers. Doctors may use prophylactic medications to try and prevent these episodes, but managing stress and developing healthy ...

Reduction of 75 and 77% seen in estimated mean monthly attack rate with 25-, 50mg NTLA-2002 vs placebo. HealthDay News — For adults with hereditary angioedema, the in vivo gene-editing therapy ...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of ...

The European Medicines Authority’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for a new drug to treat hereditary angioedema (HAE).

Kalbitor (ecallantide) is a medicine used to treat sudden attacks of hereditary angioedema (HAE). During an HAE attack, swelling happens in different areas of the body, such as your face, hands, feet, ...

Donidalorsen (Dawnzera) received FDA approval for prophylactic treatment of hereditary angioedema (HAE) in adults and kids 12 years and older, Ionis Pharmaceuticals announced on Thursday. The ...

Before 2008, treatment options for hereditary angioedema were limited. Now there are eight FDA-approved medications and even more promising therapies on the horizon. Hereditary angioedema (HAE) is a ...

A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in total plasma kallikrein protein levels compared with placebo in patients ...